The Belgian Presidency of the EU and the European Commission are organizing the Ceremonial launch of the Critical Medicines Alliance, on April 24,2024 in Brussels.
Medochemie is a member of the Critical Medicines Alliance and will participate at the event, represented by Andreas Loizou, Group Business Development Director. Supported by significant investments, Medochemie has an extensive portfolio of the EU shortlisted critical medicines, as these were defined by the Commission, which are produced at our European authorised facilities. A lot of these critical medicines produced by Medochemie also play a key role in the fight against microbial resistance as they are old molecules facing less resistance by bacteria.
The Critical Medicines Alliance is a consultative mechanism which brings together all relevant stakeholders, to identify priorities for action and propose solutions to strengthen the supply of critical medicines in the EU, to better prevent and combat their shortages.
The key objective of the Alliance is to provide an inclusive and transparent consultative platform to the European Commission and other EU decision-makers. It focuses on identifying industrial challenges and determining the most suitable actions and tools to effectively address vulnerabilities in critical medicines supply chains.
Participants in this high-level event will be the European Ministers of Health and industry, European Commissioners, participating companies, and civil society organizations, with the aim to celebrate the start of the Critical Medicines Alliance and to discuss the way forward.
See below the full list of all critical medicines produced by MEDOCHEMIE.
